mesut zengin/iStock via Getty Images Flex ( FLEX ) said Monday it agreed to acquire Electrical Power Products, a provider of engineered-to-order electrical power control and protection systems, in a deal valued at ~$1.1B, comprised of $1B in cash and $100M in anticipated tax benefits. Flex ( FLEX ) said the acquisition complements and expands its exposure to high-growth, margin-accretive end marke...
mesut zengin/iStock via Getty Images Flex ( FLEX ) said Monday it agreed to acquire Electrical Power Products, a provider of engineered-to-order electrical power control and protection systems, in a deal valued at ~$1.1B, comprised of $1B in cash and $100M in anticipated tax benefits. Flex ( FLEX ) said the acquisition complements and expands its exposure to high-growth, margin-accretive end markets shaped by long-term trends such as grid modernization, electrification, data center buildout, and U.S. reshoring. EP2 has more than 35 years of experience designing, integrating, and manufacturing highly engineered control and relay panels and modular, integrated control buildings for utility, power generation, and industrial customers. EP2 is expected to generate $323M in revenues in the fiscal year ending March 31, 2026, with anticipated double-digit organic growth and a mid- to high-teens adjusted EBITDA margin profile. More on Flex Flex Ltd. (FLEX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript Flex Q3: Not Enough Growth, Investors Didn't Like It Flex Q3 2026 Earnings Call Transcript
Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). In the 42 patient study, HRS-1893 treatment resulted in rapid and substantial reductions...
Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). In the 42 patient study, HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G), an established measure of cardiac obstruction.
By far the biggest musician to have joined the membership-based platform, Dylan’s posts have so far been puzzling – and therefore entirely in character A couple of years back, the august music writer David Hepworth came up with a great line about Bob Dylan. Dylan, he averred, “is like China: we can see what he’s doing, but never quite work out why he’s doing it”. That’s certainly true about the un...
By far the biggest musician to have joined the membership-based platform, Dylan’s posts have so far been puzzling – and therefore entirely in character A couple of years back, the august music writer David Hepworth came up with a great line about Bob Dylan. Dylan, he averred, “is like China: we can see what he’s doing, but never quite work out why he’s doing it”. That’s certainly true about the unexpected launch of the 84-year-old singer-songwriter’s Patreon . Everything about it is confusing. For one, there’s the choice of platform. Plenty of major music stars have flocked to the newsletter provider Substack in recent years to share their thoughts or show their workings and, perhaps, earn a little cash on the side: everyone from Patti Smith and Dolly Parton to Charli xcx and Rosalía. But Patreon, where fans pay monthly subscriptions for exclusive content from all sorts of creators – podcasters, visual artists – has never really taken off with big rock and pop musicians: the biggest name it could boast, until now, was Ben Folds. Continue reading...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.